Brief: TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer

Seagen

06/12/2023 13:16

Dec 6 (Reuters) - Seagen Inc  SGEN.O :
    * TUKYSA® (TUCATINIB) IN COMBINATION WITH ANTIBODY-DRUG
CONJUGATE
ADO-TRASTUZUMAB EMTANSINE IMPROVES PROGRESSION-FREE SURVIVAL IN
PATIENTS WITH PREVIOUSLY TREATED HER2-POSITIVE METASTATIC BREAST
CANCER
    * SEAGEN INC: COMBINATION SHOWED A STATISTICALLY SIGNIFICANT
IMPROVEMENT IN PROGRESSION-FREE SURVIVAL (PFS), STUDY'S PRIMARY
ENDPOINT
    * SEAGEN INC: DISCONTINUATIONS DUE TO ADVERSE EVENTS WERE
MORE
COMMON IN COMBINATION ARM OF TRIAL
    * SEAGEN INC: NO NEW SAFETY SIGNALS WERE OBSERVED FOR
COMBINATION

Source text for Eikon:  ID:nBw9HsZt9a 
Further company coverage:  SGEN.O 

 ((Reuters.Briefs@thomsonreuters.com;))